Search results for "eosinophil"

showing 10 items of 242 documents

Interleukin-5 production by mononuclear cells from aged individuals: implication for autoimmunity.

1999

It is well known that in the elderly a deterioration of immune functions may occur. Particularly, stimulation of T cells from aged individuals leads to different kind and/or size of responses if compared with the responses obtained from T cells from young individuals. At the same time, an increase in prevalence of autoantibodies occurs in elderly. The altered production of certain cytokines might explain this paradox of decreased responsiveness to foreign antigens in the face of an increased response to self-antigens. We and others have suggested that this kind of immune response might depend on an age-associated impairment of Th-1 type function that selectively affects production of cytoki…

AdultMalemedicine.medical_specialtyAgingmedicine.medical_treatmentT-LymphocytesAutoimmunityEnzyme-Linked Immunosorbent AssayBiologymedicine.disease_causeLymphocyte ActivationPeripheral blood mononuclear cellAutoimmunityImmune systemAntigenInternal medicinemedicineHumansInterleukin 5Cells CulturedAgedAged 80 and overB-LymphocytesAutoantibodyImmunosenescenceMiddle AgedImmunoglobulin AEosinophilsEndocrinologyCytokineImmunologyFemaleInterleukin-5Developmental BiologyMechanisms of ageing and development
researchProduct

Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens.

1998

The efficacy and tolerance of short-term immunotherapy (STI) by seven preseasonal injections of tree-pollen allergens (ALK7 Fruhbluhermischung) was investigated in a double-blind, placebo-controlled, multicenter study with 111 rhinoconjunctivitis patients. Nasal and bronchial symptoms simultaneously analyzed, and nasal symptoms as a single end point, but not the overall score of nasal, bronchial, and conjunctival symptoms, showed a significantly lower increase with STI during birch-pollen exposure (both P=0.033, n=105, Mann-Whitney U-test). However, a selective analysis with patients from centers with high recruitment figures (n> or =10 patients, n=29 STI, n=32 placebo) showed a significant…

AdultMalemedicine.medical_specialtyAllergyTime FactorsAdolescentmedicine.medical_treatmentImmunologyPlaceboImmunoglobulin Emedicine.disease_causeGastroenterologyInjectionsTreesAllergenRibonucleasesDouble-Blind MethodInternal medicineImmunopathologyotorhinolaryngologic diseasesImmunology and AllergyMedicineHumansDesensitization (medicine)Conjunctivitis AllergicSkin TestsEosinophil cationic proteinbiologybusiness.industryRhinitis Allergic SeasonalBlood Proteinsrespiratory systemAllergensEosinophil Granule ProteinsImmunoglobulin EMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeDesensitization ImmunologicImmunoglobulin GImmunologybiology.proteinPollenFemalebusinessAllergy
researchProduct

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

2018

Background Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. Objective We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma (SEA). Methods COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859 ) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT01000506 ). Patients received 100 mg of subcutaneous mepolizumab every 4 weeks plus standard of care until a protocol-def…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsExacerbationInjections Subcutaneous[SDV]Life Sciences [q-bio]ImmunologyEosinophilic asthmaAntibodies Monoclonal HumanizedPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodSurveys and QuestionnairesInternal medicineEosinophiliamedicineHumansImmunology and AllergyIn patientAnti-Asthmatic Agents030212 general & internal medicineAdverse effectRespiratory Tract InfectionsComputingMilieux_MISCELLANEOUSAsthmabusiness.industryMiddle Agedmedicine.diseaseAsthma3. Good healthEosinophils[SDV] Life Sciences [q-bio]Treatment Outcome030228 respiratory systemAsthma Control QuestionnaireBronchitisFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct

Measurement of inflammatory mediators of eosinophils and lymphocytes in blood in acute asthma: serum levels of ECP influence the bronchodilator respo…

2002

The aim of this study was to assess the relevance of immunoinflammatory markers on the response to short acting β<sub>2</sub>-agonist in acute asthma exacerbation. Thus, we measured serum eosinophil cationic protein (ECP) levels and sIL-2R at acute exacerbation in 52 adult patients with atopic asthma, and assessed forced expiratory volume in 1 s (FEV<sub>1</sub>) before and after the administration of aerosolized salbutamol. After a cumulative dose of salbutamol causing a 10% improvement in FEV<sub>1</sub> from baseline [CD10, i.e. cumulative doses of salbutamol (800 µg) causing an improvement in FEV<sub>1</sub> from baseline to 10%] the patie…

AdultMalemedicine.medical_specialtyExacerbationAdolescentmedicine.drug_classImmunologyStatistics NonparametricRibonucleasesInternal medicineBronchodilatorForced Expiratory VolumemedicineImmunology and AllergyHumansAlbuterolAsthmaSkin TestsEosinophil cationic proteinCumulative dosebusiness.industryReceptors Interleukin-2General MedicineBlood Proteinsrespiratory systemEosinophilAdrenergic beta-AgonistsEosinophil Granule ProteinsImmunoglobulin EMiddle Agedmedicine.diseaseBlood proteinsAsthmarespiratory tract diseasesBronchodilator AgentsEndocrinologymedicine.anatomical_structureImmunologySalbutamolFemalebusinessmedicine.drugInternational archives of allergy and immunology
researchProduct

Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma.

2019

ARIETTA was a prospective, single-arm, noninterventional, multicenter study in patients with severe asthma.To examine the predictive and prognostic abilities of type 2 biomarkers for severe asthma outcomes.Adult patients with severe asthma receiving daily inhaled corticosteroids (fluticasone propionate ≥500 μg or equivalent) and ≥1 second controller medication were enrolled. Biomarker, clinical, and safety data were collected over 52 weeks. The primary endpoint was the asthma exacerbation rate over 52 weeks in serum periostin-high (≥50 ng/mL at baseline) versus periostin-low subgroups (50 ng/mL). Correlations between biomarker levels (periostin, blood eosinophils, IgE, and fractional exhale…

AdultMalemedicine.medical_specialtyExacerbationRate ratioImmunoglobulin ENitric OxideGastroenterologyFluticasone propionate03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineClinical endpointImmunology and AllergyHumans030212 general & internal medicineLongitudinal StudiesProspective Studiesbiologybusiness.industryConfidence intervalAsthma3. Good healthEosinophils030228 respiratory systembiology.proteinBiomarker (medicine)FemalebusinessBiomarkersmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

The Severe Asthma Network in Italy: Findings and Perspectives

2019

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean …

AdultMalemedicine.medical_specialtyRegistrySevere asthmaExacerbationBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Immunology and AllergyOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioComorbiditiesAtopy03 medical and health sciencesBronchiectasi0302 clinical medicineFood allergyInternal medicineLate-onset asthmaNasal polypsBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Adult; Aged; Asthma; Bronchiectasis; Comorbidity; Eosinophils; Female; Humans; Immunoglobulin E; Italy; Male; Middle Aged; Nasal Polyps; Registries; RhinitisMedicineHumansBronchiectasis Comorbidities Late-onset asthma Nasal polyps Registry SANI Severe asthma Immunology and AllergyImmunology and Allergy030212 general & internal medicineRegistriesAsthmaAgedRhinitisBronchiectasisbusiness.industryNasal polypSANIImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaBronchiectasisEosinophils030228 respiratory systemItalyAsthma Control QuestionnaireFemaleComorbiditiebusinessMepolizumabmedicine.drug
researchProduct

Oligo-antigenic diet in the treatment of chronic anal fissures. Evidence for a relationship between food hypersensitivity and anal fissures.

2013

Abstract OBJECTIVES: Patients with chronic constipation due to food hypersensitivity (FH) had an elevated anal sphincter resting pressure. No studies have investigated a possible role of FH in anal fissures (AFs). We aimed to evaluate (1) the effectiveness of diet in curing AFs and to evaluate (2) the clinical effects of a double-blind placebo-controlled (DBPC) challenge, using cow's milk protein or wheat. METHODS: One hundred and sixty-one patients with AFs were randomized to receive a "true-elimination diet" or a "sham-elimination diet" for 8 weeks; both groups also received topical nifedipine and lidocaine. Sixty patients who were cured with the "true-elimination diet" underwent DBPC cha…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaConstipationManometryTreatment outcomeFood habitsSettore MED/08 - Anatomia PatologicaGastroenterologyFissure in anolaw.inventionLeukocyte CountFeeding behaviorRandomized controlled trialDouble-Blind MethodlawRecurrenceInternal medicinemedicineHumansLymphocyte CountLymphocytesIntestinal MucosaTriticumHepatologybusiness.industryGastroenterologyFeeding BehaviorMiddle AgedMilk ProteinsSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheFood hypersensitivitySurgeryEosinophilsSettore MED/18 - Chirurgia GeneraleChronic diseaseTreatment OutcomeChronic DiseasefissureFemaleFissure in Anohypersensitivitymedicine.symptomMilk HypersensitivitybusinessConstipationFood HypersensitivityThe American journal of gastroenterology
researchProduct

Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome.

2011

Background & Aims Some patients with irritable bowel syndrome (IBS)-like symptoms suffer from food hypersensitivity (FH); their symptoms improve when they are placed on elimination diets. No assays identify patients with FH with satisfactory levels of sensitivity. We determined the frequency of FH among patients with symptoms of IBS and the ability of fecal assays for tryptase, eosinophil cationic protein (ECP), or calprotectin to diagnose FH. Methods The study included 160 patients with IBS, 40 patients with other gastrointestinal diseases, and 50 healthy individuals (controls). At the start of the study, patients completed a symptom severity questionnaire, fecal samples were assayed, and …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaFecal Calprotectin.AdolescentGlutensTryptaseWheat HypersensitivityGastroenterologyIrritable Bowel SyndromePlacebosFecesYoung Adultfluids and secretionsDouble-Blind MethodInternal medicineElimination dietmedicineHumansIrritable bowel syndromeFeceschemistry.chemical_classificationEosinophil cationic proteinHepatologybiologybusiness.industryOral food challengeEosinophil Cationic ProteinGastroenterologyMiddle Agedmedicine.diseaseGlutenDietchemistryGluten SensitivityImmunologybiology.proteinFemaleTryptasesCalprotectinCow’s Milk Protein HypersensitivityMilk HypersensitivitybusinessLeukocyte L1 Antigen ComplexCow’s Milk Protein Hypersensitivity; Gluten Sensitivity; Fecal Tryptase; Fecal Eosinophil Cationic Protein; Fecal Calprotectin.Fecal TryptaseFecal Eosinophil Cationic ProteinClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

2019

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaTreatment outcomeMEDLINEOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin Eeosinophil Omalizumab anti-IgE asthmaLeukocyte CountText miningForced Expiratory VolumeInternal medicineEosinophiliamedicineHumansImmunology and AllergyAnti-Asthmatic AgentsBlood eosinophilAgedRetrospective StudiesAsthmabiologybusiness.industryRetrospective cohort studyMiddle AgedasthmaPrognosismedicine.diseaseEosinophilsTreatment Outcomeinflammationbiology.proteinFemalebusinessmedicine.drug
researchProduct

Analysis of cytokine and specific antibody profiles in hydatid patients with primary infection and relapse of disease

1998

We studied in vitro cytokine production by peripheral blood mononuclear cells (PBMC) from patients with primary and recurrent hydatid disease when cells were incubated with mitogen (PHA) and antigen from hydatid cyst fluid (HCFAg); levels of specific IgE, IgG4 and eosinophil counts were also measured in sera. When specifically stimulated, PBMC from patients produced higher levels of IL-2 (P < 0.02), IFN-γ (P < 0.0028) and IL-5 (P < 0.01) than those from uninfected donors, whereas IL-10 levels were comparable. Notably, IL-5 was also produced in higher levels (P < 0.01) by PBMC from patients when incubated with PHA. The IL-5:IFN-γ ratio was significantly greater (P < 0.02) when measured in re…

AdultMalemedicine.medical_treatmentImmunologyAntibodies HelminthBlood DonorsCell CountStimulationDiseaseImmunoglobulin EPeripheral blood mononuclear cellAntigenEchinococcosisRecurrencemedicineAnimalsHumansPhytohemagglutininsCells CulturedAgedbiologybusiness.industryMiddle AgedEosinophilIn vitroEosinophilsmedicine.anatomical_structureCytokineAntigens HelminthImmunologyLeukocytes Mononuclearbiology.proteinCytokinesCattleFemaleParasitologyMitogensbusinessCell DivisionParasite Immunology
researchProduct